miR-128 was shown to specifically inhibit insulin receptor (INSR) and insulin receptor substrate 1 (IRS1) to abate glycolytic signaling pathway and mitochondrial respiration, resulting in decreased tumor growth [33]. This evidence concerns the gene INSR and neoplasm.